NCT03162731View on ClinicalTrials.gov

Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 11, 2017

Primary Completion Date

September 27, 2020

Study Completion Date

November 16, 2022

Conditions
LarynxLip, Oral Cavity and Pharynx
Interventions
BIOLOGICAL

Nivolumab

Given IV

BIOLOGICAL

Ipilimumab

Given IV

RADIATION

Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy

Undergo simultaneous integrated boost integrated modulated radiation therapy

RADIATION

Volume Modulated Arc Therapy

Undergo volumetric modulated arc therapy

Trial Locations (1)

19107

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER

NCT03162731 - Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer | Biotech Hunter | Biotech Hunter